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Abstract
Background: Pulmonary alveolar proteinosis (PAP) is a syndrome with multiple etiologies and is often deadly in
lysinuric protein intolerance (LPI). At present, PAP is treated by whole lung lavage or with granulocyte/monocyte
colony stimulating factor (GM-CSF); however, the effectiveness of GM-CSF in treating LPI associated PAP is
uncertain. We hypothesized that GM-CSF and surfactant protein D (SP-D) would enhance the clearance of
proteins and dying cells that are typically present in the airways of PAP lungs.
Methods: Cells and cell-free supernatant of therapeutic bronchoalveolar lavage fluid (BALF) of a two-year-old
patient with LPI were isolated on multiple occasions. Diagnostic BALF samples from an age-matched patient with
bronchitis or adult PAP patients were used as controls. SP-D and total protein content of the supernatants were
determined by BCA assays and Western blots, respectively. Cholesterol content was determined by a calorimetic
assay or Oil Red O staining of cytospin preparations. The cells and surfactant lipids were also analyzed by
transmission electron microscopy. Uptake of Alexa-647 conjugated BSA and DiI-labelled apoptotic Jurkat T-cells
by BAL cells were studied separately in the presence or absence of SP-D (1 μg/ml) and/or GM-CSF (10 ng/ml), ex
vivo. Specimens were analyzed by light and fluorescence microscopy.
Results: Here we show that large amounts of cholesterol, and large numbers of cholesterol crystals, dying cells,
and lipid-laden foamy alveolar macrophages were present in the airways of the LPI patient. Although SP-D is
present, its bioavailability is low in the airways. SP-D was partially degraded and entrapped in the unusual
surfactant lipid tubules with circular lattice, in vivo. We also show that supplementing SP-D and GM-CSF increases
the uptake of protein and dying cells by healthy LPI alveolar macrophages, ex vivo. Serendipitously, we found that
these cells spontaneously generated granulomas, ex vivo, and GM-CSF treatment drastically increased the number
of granulomas whereas SP-D treatment counteracted the adverse effect of GM-CSF.
Conclusions:  We propose that increased GM-CSF and decreased bioavailability of SP-D may promote
granuloma formation in LPI, and GM-CSF may not be suitable for treating PAP in LPI. To improve the lung
condition of LPI patients with PAP, it would be useful to explore alternative therapies for increasing dead cell
clearance while decreasing cholesterol content in the airways.
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Background
Pulmonary alveolar proteinosis (PAP) syndrome is
thought to occur due to multiple causes including genetic
defects [1-3], immune deficiencies [4], malignancies [5,6]
and infection [7]. Patients with PAP have milky alveolar
infiltrates that often contain excess surfactant material
and large numbers of white blood cells. PAP is usually
treated by whole lung lavage (WLL) [8-12] or with GM-
CSF administration [13-16]. GM-CSF is a hematopoietic
growth factor known to stimulate stem cells to proliferate
into granulocytes or monocytes [17], promote differentia-
tion of monocytes into alveolar macrophages [18-20],
and increase the catabolism within alveolar macrophages
[21,22], and increase the innate immune potential of neu-
trophils [23]. Therefore, GM-CSF is an important cytokine
that could regulate PAP at multiple levels.
PAP-like condition is also reported in surfactant protein D
(SP-D) deficient mice [24-26]. SP-D is an innate immune
collectin that is present in lungs and other mucosal sur-
faces [27]. It opsonizes pathogens and dying cells, and
enhances their uptake by the alveolar macrophages
[28,29]. SP-D deficient mice also accumulate lipid-laden
foamy macrophages [25,26] and apoptotic cells in their
lungs [30]. Moreover, transgenic over-expression of SP-D
[31] or administration of recombinant fragments of SP-D
[30] has been shown to enhance immune function in the
lungs in mice. Therefore, SP-D and GM-CSF could signifi-
cantly enhance the innate immune functions of alveolar
macrophages.
PAP is one of the deadliest phenotypes seen in Lysinuric
protein intolerance (LPI) [32-34]. LPI is an autosomal
recessive disorder characterized by mutations in the
SLC7A7 (solute carrier family 7, member 7) gene, which
encodes a dibasic cationic amino acid transporter, y+LAT1
[35,36]. Mutant SLC7A7 proteins cause defective trans-
port of the cationic amino acids arginine, lysine, and orni-
thine [35-38]. PAP develops in some LPI patients and
appears to be different from idiopathic PAP [32]. PAP in
LPI presents with large numbers of cholesterol crystals
and granulomas [32,33,39]. The precise cause or appro-
priate treatment options for the clinical presentation of
PAP in LPI is currently unknown. Since LPI is not a well-
characterized disease, and has multiple symptoms [37], it
may have also been misdiagnosed as other conditions,
and hence, the prevalence of this disease may be higher
than the reported numbers [37]. Therefore, it is important
to study the disease phenotypes and treatment options.
We hypothesized that defective clearance of materials
present in the airways contributes to the presentation of
PAP in LPI patients, and treating the LPI cells with SP-D
and GM-CSF could enhance the innate immune potential
of these cells.
Consistent with our hypothesis, we found that SP-D and
GM-CSF increase the uptake of proteins and dying cells by
LPI AMs. Unexpectedly, we found that the LPI AMs spon-
taneously formed granulomas, ex vivo. Moreover, while
control cells remained unchanged, the addition of GM-
CSF to the LPI AM cultures resulted in a marked increase
in the number of granulomatous structures. Notably, SP-
D counteracted the negative effect of GM-CSF. In conclu-
sion, although GM-CSF may have therapeutic advantage
in certain types of PAPs, it may not be suitable for treating
PAP of the LPI patients.
Materials and methods
Mutation analysis
SLC7A7 gene mutation analysis was performed by Dr.
Ginafranco Sebastio in Naples, Italy. ABCA3, SP-B and SP-
C genes were sequenced and analyzed by Ambrey Genet-
ics.
Reagents
All buffer salts and reagents were obtained from Sigma
unless otherwise stated. SP-D was isolated from BALF of
an adult PAP patient as described previously [40,41].
Recombinant GM-CSF expressed in yeast (Leukine) was
produced by Berlex (Seattle, WA). All cell culture media
were obtained from Invitrogen (Carlsbad, CA).
Collection of WLL and BALF
Therapeutic WLL was performed in the LPI patient or idi-
opathic PAP patient, and the BALF samples were colleted
in 100 ml vials. Diagnostic BALF sample was also
obtained from another airway disease patient. BALF was
filtered with nylon mesh and centrifuged at 200 × g for 10
min at 4°C. The pellets containing the cells were then
washed twice with Hank's Buffered Salt Solution (HBSS).
The supernatant was centrifuged again at 10,000 × g for 40
min at 4°C to collect surfactant lipid pellets, which were
stored at -80°C until further analyses.
Analysis of the BALF
BCA® Protein Assay kit from Pierce (Rockford, IL) was
used for measuring the protein concentrations in the pre-
filtered BALF from each collection vial according to the
manufacturer's instructions. SP-D concentration levels
and degradation were assessed in the BALF from the LPI
patient by Western blotting using anti-human SP-D rabbit
sera as described previously [42]. An aliquot of the BALF
from each collectin tube was immediately mixed with
0.2% (w/v) Trypan Blue solution and counted using a
Hemocytometer at 20× or 40× normal magnification. The
amount of cholesterol present in the BALF samples were
assessed using the Cholesterol Assay Kit (Cayman Chem-
ical Co., Ann Arbor, MI).Orphanet Journal of Rare Diseases 2009, 4:29 http://www.ojrd.com/content/4/1/29
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Histological staining
Cytospin preparations were made using 50 and 100 μl
BALF, cells were air dried and subjected to Hemacolor®
staining (EMD Chemicals, Inc, Gibbstown, NJ) for histo-
logical analysis. Other cytospin preparations were fixed
with 2% (v/v) paraformaldehyde (PFA) in PBS for 1 h at
4°C, and were subjected to staining with Oil Red O (Poly-
sciences, Inc, Washington, PA) for lipid analysis of foamy
macrophage cells. Oil Red O stock solution was prepared
by dissolving 0.5% (w/v) Oil Red O powder in isopropa-
nol at 37°C. This stock solution was then diluted to 60%
(v/v) with dH2O to make the working solution. Cytospin
preparation of cells were rinsed with 60% (v/v) isopropa-
nol, and stained with freshly prepared Oil Red O working
solution for 15 min and counterstained with Hemacolor
Solution 3 for nuclei. Cells were imaged using Leitz Labor-
lux D microscope with Leica IM 50 image manager soft-
ware.
Electron microscopy
Cell pellets and surfactant lipid pellets obtained from 200
× g and 10,000 × g centrifugation of BALF, respectively,
were fixed for at least 18 h at 4°C with 2% (v/v) parafor-
maldehyde (PFA) and 4% (v/v) glutaraldehyde (Electron
Microscopy Sciences, Fort Washington, PA) in a buffer
containing 50 mM HEPES (pH 7.4), 150 mM NaCl, and 1
mM CaCl2. Samples were then processed, stained with 2%
(w/v) uranyl acetate and analyzed by transmission elec-
tron microscopy (JEOL TEM 1011) with AMT Image Cap-
ture Engine software at 2,000-40,000 times normal
magnification.
Cell culture
Cell pellets obtained from 200 × g centrifugation of the
BALF were immediately re-suspended in Dulbecco's Mod-
ified Eagle's Medium (DMEM) supplemented with 10%
(v/v) heat-inactivated Fetal Bovine Serum (FBS) with 100
U/ml penicillin, 100 μg/ml streptomycin, and 2.5 μg/ml
Fungezone. Cells were then allowed to adhere to chamber
slides or 24- or 48-well culture plates for 1 h, and non-
adherent cells were washed. Cells were cultured in the
same media, and subsequently, the media was changed to
Macrophage Serum-Free Media (MSFM), a specific media
available for culturing macrophage cells (Invitrogen), and
does not require supplementation with serum, prior to
the experiments. The Jurkat T cell line was maintained in
RPMI containing 10% (v/v) FBS.
Induction of apoptosis
Jurkat T cells were first labelled with 2 μl/ml DiI mem-
brane dye (Invitrogen) in MSFM for 4 min at 37°C, fol-
lowed by three washes with HBSS. Apoptosis was induced
by UVC irradiation for 30 s using UV Stratalinker 2400
(120 J/cm2). Cells were then placed in the humidified
incubator at 37°C for 2 h in the absence or presence of SP-
D (5 μg/ml).
BSA/Apopotic cell uptake assay
Cells were incubated first in MSFM overnight prior to the
experiment. Cells were then treated with SP-D (1 μg/ml)
for 4 h, and GM-CSF (10 ng/ml) for 30 min prior to the
experiment. Alexa-647 conjugated BSA was added to the
culture for 30 min, at which point the cells were fixed with
2% (v/v) PFA for 10 min at room temperature, followed
by fresh 2% (v/v) PFA for 1 h at 4°C. DiI-labelled apop-
totic Jurkat T cell uptake assay was performed in the same
manner as BSA using the Jurkat cells 2 h after the induc-
tion of apoptosis (1:5 of apoptotic cells:macrophages).
Fluorescence microscopy and image analysis
Images for the uptake assays, and granuloma assay were
captured using Zeiss Axiovert 200 M fluorescence micro-
scope with Volocity software. Measurement of cell area,
color (label-specific gray levels) and size was performed
using Volocity software.
Granuloma formation assay
Cells were incubated in the presence or absence of SP-D (1
μg/ml) and/or GM-CSF (10 ng/ml) for 29 days ex vivo.
Culture media was replaced with a fresh media with the
addition of appropriate reagents (SP-D and/or GM-CSF)
every 3-5 days. After 28 days, the granulomas started to
dislodge from the substratum.
Statistical analysis
A two-tailed student's t-test was performed using Micro-
soft Excel on Oil Red O positive cell counting and apop-
totic Jurkat cell uptake analysis. Protein uptake assay, and
cell shape and size were analyzed using Dunnett's multi-
ple mean comparison tests using JMP statistical analysis
software (Version 5.0; SAS Institute Inc.). A p-value was
set at 0.05 for statistical significance. Non-linear regres-
sion analysis and comparisons of regression lines by
ANOVA and F-test was performed using GraphPad PRISM
statistical analysis software (Version 4.0; GraphPad Soft-
ware).
Results
LPI and control patients
A Canadian boy with Dutch ancestry was diagnosed with
LPI at 9 months of age. His symptoms included feeding
difficulty, vomiting, hepatomegaly and failure to thrive.
Symptoms improved after initiating dietary therapy with
protein restriction and citrulline supplementation. How-
ever, a progressive productive cough developed by age 18
months. Chest X-rays showed an interstitial pneumonitis
pattern and bronchiolar lavage fluid confirmed the pres-
ence of Periodic acid-Schiff (PAS) stain positive staining
alveolar macrophages consistent with the diagnosis ofOrphanet Journal of Rare Diseases 2009, 4:29 http://www.ojrd.com/content/4/1/29
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PAP. The patient, however, did not have mutations in
ABCA3, SP-B, or SP-C. Despite appropriate dietary therapy
and treatment of gastro-esophageal reflux, the boy's respi-
ratory symptoms progressed and he developed a persist-
ent oxygen need. A trial of systemic steroid therapy (2 mg/
kg body weight) was ineffective. At 2 1/2 years of age refer-
ral was made to our pediatric respiratory medicine service.
Since WLL is associated with significant morbidity and
technically difficult in small children, a three-month trial
of inhaled GM-CSF (250 μg once daily delivered through
a pari-star nebulizer with a mouthpiece) was instituted.
The boy's respiratory deterioration continued. Therefore,
a WLL procedure was performed after the discontinuation
of GM-CSF treatment. After the procedure, there seemed
to be some initial clinical improvement, but the respira-
tory symptoms relapsed within 3 to 5 days. His disease
progressed to the point of respiratory failure requiring
intubation and mechanical ventilation despite two further
lung lavages. A lung biopsy only confirmed the diagnosis
of PAP and interstitial pneumonitis secondary to LPI. The
presence of cholesterol granulomas in the airways was
also confirmed by the biopsy. The boy was unresponsive
to further courses of high dose pulse intravenous corticos-
teroid therapy and eventually died.
Diagnostic BALF samples from a patient who had bron-
chitis of unknown etiology and no specific airways disease
were used as a control. In some experiments, we also used
BALF samples obtained from adult idiopathic PAP
patient.
BALF contains high levels of protein and dying cells
To determine the alterations in the proteins present in the
patient's airways, we analyzed the lavage samples by BCA
assay. Large quantities of proteins were present in the
patient's airways, and the protein content gradually
decreased in successive collection aliquots (Figure 1A).
Compared to the control BALF, the protein concentration
in the airways of the LPI patient was over 100-fold higher
in the first lavage (Figure 1B). Although repeated BAL pro-
cedures across different procedural days (BAL2, 3, and 4)
and different lobes reduced the protein concentration,
they remained over 30-fold higher compared to control
(Figure 1B). In addition to increased protein concentra-
tion, large numbers of dead/dying cells were present in
these samples as revealed by Trypan blue exclusion assays
(Figure 1C). On average, approximately 40% dying cells
were present in these LPI BALF samples.
Reduced bioavailability of SP-D in LPI PAP surfactant
The role of SP-D in human PAP is not well understood.
Using multiple LPI PAP lavage samples from the patient,
we first determined whether there were any alterations in
SP-D. Western blots detected SP-D that was either modi-
fied or tightly associated with other components present
in the airways (upward smear) as well degraded SP-D (low
molecular weight bands) (Figure 1D). This suggested that
the bioavailability of functional SP-D would be low in
these airways. To further assess this point, we analyzed the
surfactant lipids isolated from the supernatant obtained
after removing the cell pellet. The surfactant lipid isola-
tion was performed by a subsequent centrifugation of this
supernatant at high-speed (10,000 × g). We first examined
the surfactant lipid structure in detail. Lattice-like tubular
myelin structure was detected in the surfactant lipid (Fig-
ure 1E, arrowhead). There were also many amorphous
electron-dense structures present (Figure 1E, arrow).
Notably, the PAP surfactant also contained unusual forms
of tubular myelin with circular lattices (Figure 1F). This
circular tubular myelin had the cross-sectional diameter
of approximately 90 nm, with electron dense "spot" in its
centre, a structure similar to that of SP-D mediated tubular
myelin [43]. These unusual structures indicated that SP-D
is likely trapped inside these tubular structures. The pres-
ence of atypical circular tubular myelin and the cleaved/
modified collectin suggested that the bioavailability of SP-
D would be low in these airways.
LPI PAP BALF contains abundant cholesterol and foamy 
cells
To determine the cholesterol level in the surfactant, we
measured the amount of cholesterol present in the LPI
BALF. The LPI BALF contained over 60-fold higher
amounts of cholesterol compared to the control samples
(Figure 2A). This is particularly important as serum cho-
lesterol levels in the LPI patient were found to be in the
normal range (data not shown). We also detected many
needle-like cholesterol crystals in the lipid pellet, ranging
from 2 μm to over 30 μm in length (Figure 2B)
To characterize the different types of immune cells present
in the airways, cytospin preparations were made from
BALF, fixed and stained with Oil Red O, a dye that prima-
rily stains neutral lipids, triglycerides and lipoproteins
(Figure 2C). While few cells from bronchitis control BALF
were Oil Red O positive, a significantly higher percentage
of cells stained positive in the LPI BALF indicating the
presence of lipid-laden foamy macrophage cells (> 20-
fold; p < 0.05; Figure 2C). To further confirm the nature of
these cells, cells were isolated from BALF samples and
examined using electron microscopy. Large numbers of
vacuolated foamy macrophages, other immune cells,
small-sized apoptotic cells with condensed nuclei and cel-
lular debris were readily detected (Figure 2D). Further-
more, foamy cells that contain cholesterol crystals within
their cytoplasm were often observed (Figure 2E). Large
cholesterol needles were also present outside the cells in
these preparations. Collectively, these results demon-
strated that the LPI patient had PAP with multiple altera-
tions potentially impairing lung function.Orphanet Journal of Rare Diseases 2009, 4:29 http://www.ojrd.com/content/4/1/29
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LPI alveolar macrophage cells respond to SP-D and GM-
CSF during uptake of protein and apoptotic cells
We then sought to determine whether SP-D and/or GM-
CSF would enhance the uptake of various components
typically present in the PAP airways by LPI alveolar mac-
rophages. To assess this, we tested whether the uptake of
protein (Alexa-647 conjugated BSA) and apoptotic Jurkat
cells could be increased in the presence of SP-D and/or
GM-CSF (Figure 3). Among the cultured BAL cells,
"healthy" cells with alveolar macrophage morphology
readily adhered to the culture plates for long period of
time. However, the foamy cells did not survive the cultur-
ing conditions, and did not show detectable uptake of
labeled protein (Figure 3A); thus, these healthy cells were
used for the subsequent experiments (Figure 3B-E). For
this, BAL cells that were collected by centrifugation of
BALF at low speed (200 × g) and plated in chamber slides
were cultured. In the uptake assays, these cells were pre-
incubated with SP-D (1 μg/ml) for 4 h, and/or with GM-
CSF (10 ng/ml) for 30 min prior to feeding (Figure 3B and
3D). In general, qualitative examination showed that pre-
incubation of cells with SP-D and GM-CSF enhanced the
uptake of Alexa-647 BSA by the BAL cells. In order to
quantify the uptake of Alexa-647 BSA, we manually
counted different types of BSA uptake of randomly
selected cells from the images (double blinded) using a
sorting system. The counting categories consisted of "Cell
Periphery", "Uniform Distribution", "Perinuclear" and
"No Uptake". Of those categories, "Uniform Distribu-
tion" and "Perinuclear" categories were considered sepa-
rate because the internalized materials are processed
within the cells by fusing with lysosomes, which are pri-
marily located in large numbers in the perinuclear regions
of the cells [44]. We inferred that the increase in the
number of cells in "Perinuclear" category would be an
increase in the processing rate of the internalized material.
Compared with buffer control, co-incubation of cells with
both SP-D and GM-CSF significantly increased the pro-
portion of cells belonging to perinuclear category (p <
0.05; Figure 3B). Therefore, we infer that the presence of
both SP-D and GM-CSF enhances the uptake/clearance of
proteins by LPI macrophages.
SP-D deficiency results in the accumulation of apoptotic
cells,  in vivo [30], and PAP airways contain increased
number of dead cells (Figures. 1 and 2). Thus, we next
asked whether SP-D and/or GM-CSF could enhance the
clearance of apoptotic cells by the cells isolated from the
LPI BALF (Figure 3C and 3E). These cells were incubated
with apoptotic Jurkat T cells for 4 h in the presence/
absence of SP-D and/or GM-CSF. SP-D was pre-incubated
with apoptotic cells after the induction of apoptosis with
UV irradiation. We manually quantified the images of
cells as either "Uptake" where the cells have taken up
apoptotic cell material, and "No Uptake". Manual count-
ing of randomly selected images (double blinded)
revealed that, like BSA uptake, the uptake of apoptotic
cells/bodies was significantly increased when macro-
phages were incubated with SP-D coated apoptotic cells in
the presence of GM-CSF (p < 0.05; Figure 3C).
SP-D and GM-CSF affect the cell size and shape
We next asked whether SP-D and GM-CSF alter the cells
isolated from BALF. Analysis of randomly selected images
obtained from the feeding experiments showed that SP-D
and GM-CSF affect the shape and size (as defined by the
area occupied by each cell) of the cells (Figure 4). While
control cells consisted of relatively uniform shapes and
sizes (Figure 4A), the presence of SP-D promoted cell
spreading (Figure 4B) and GM-CSF made cells more
spherical/oval in shape (Figure 4C). Presence of both SP-
D and GM-CSF generated mixed populations of both
elongated and spherical cells (Figure 4D). Measurement
of cell size also showed that GM-CSF, both in the presence
and absence of SP-D, caused a significant decrease in cell
size (p < 0.05; Figure 4E). Thus, these results show that SP-
D may increase cell spreading, whereas GM-CSF main-
tains cells in a spherical shape.
The airways of LPI lungs with PAP contain high levels of protein, dying cells and has low bioavailability of SP-D Figure 1 (see previous page)
The airways of LPI lungs with PAP contain high levels of protein, dying cells and has low bioavailability of SP-D. 
(A) BCA assay results showing the protein concentrations of the BALF in each collectin vial (left lung). Protein concentration 
gradually decreased with subsequent lavages. No noticeable changes in protein concentrations occur after about 10 washes 
with 100 ml saline each. (B) Protein concentrations determined by BCA assay on the samples present in the first collection vial 
of four lavages conducted on separate occasions. BAL1, left lung; BAL2-4, right lung. Control sample was obtained from a diag-
nostic BAL from a patient with bronchitis. (C) Trypan blue exclusion assay showing the dead cells present in the BALF. Values 
represent the % of dead cells present in the total cells isolated from the BALF. (D) Western blot for SP-D. Initial lavage sam-
ples contained slowly migrating SP-D (smear). Later samples show multiple SP-D bands with lower molecular weights sugges-
tive of degraded SP-D fragments. (E and F) LPI lung surfactant contains altered atypical tubular myelin with circular lattice. TEM 
analysis was performed on lipid pellet isolated from 10,000 × g centrifugation of cell-free LPI BALF. (E) High abundance of 
amorphous electron dense lipid-droplet like material (arrow) and some classical SP-A-mediated tubular myelin structures with 
square lattice-like structures are seen (arrowhead). (F) Large numbers of atypical tubular myelin structures with circular lat-
tices and a central electron dense dot are also detected (~90 nm diameter; arrows). Bar, 100 nm (E and F).Orphanet Journal of Rare Diseases 2009, 4:29 http://www.ojrd.com/content/4/1/29
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The airways of LPI lungs contain high amount of cholesterol, cholesterol needles and foamy macrophage cells Figure 2
The airways of LPI lungs contain high amount of cholesterol, cholesterol needles and foamy macrophage cells. 
(A) Cholesterol assay revealed over 60-fold increase in cholesterol level of LPI BALF compared to controls. Control samples 
were obtained from diagnostic BALF of a patient with bronchitis (BRO) and a patient who carries mutation in ABCA3 trans-
porter (ABCA3). (B) Several needle-like structures reminiscent of cholesterol crystals (arrows) are present within LPI sur-
factant lipid. Bar: 10 μm. (C) Quantitative analysis show that a significantly higher numbers of Oil Red O positive cells are 
present in LPI BALF compared to control BALF. The inset image shows representative large and foamy Oil Red O positive cells 
(arrows). Data are expressed as the mean percentage of positive cells in total cells ± SEM. Student's t-test was performed with 
* p < 0.05. (D) Transmission electron microscopy of cell pellets obtained from 200 × g centrifugation of LPI BALF shows the 
presence of lipid-laden foamy macrophage cells (arrow) and dying cells and/or lymphocytes in LPI BALF. (E) Many of the alveo-
lar macrophages contained needle-like cholesterol crystals in their cytoplasm. Several long extracellular cholesterol needles are 
also visible (top right). Bar, 10 μm.Orphanet Journal of Rare Diseases 2009, 4:29 http://www.ojrd.com/content/4/1/29
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Adherent viable cells isolated from LPI BALF respond to SP-D and GM-CSF and increase uptake of protein and dying cells Figure 3
Adherent viable cells isolated from LPI BALF respond to SP-D and GM-CSF and increase uptake of protein 
and dying cells. (A) LPI BALF contained foamy macrophage cells that did not take up protein. These cells did not survive even 
an over night culturing, and thus, was not included in the quantification of uptake index. (B) Pre-treatment of primary cells iso-
lated from the BALF with SP-D and GM-CSF facilitate the transport of Alexa-647 conjugated BSA to perinuclear regions. Cells 
were quantified and presented as means ± SEM of percentage of cells. n = three independent experiments. At least 70 cells 
were counted for each condition. Uptake index represents the proportion of cells that have Alexa-647 signal in the perinuclear 
region out of total cell present. The means were compared with respective controls using Dunnett's multiple mean compari-
son procedure (* p < 0.05). (C) Presence of SP-D and GM-CSF increase the uptake of apoptotic cells by LPI BAL cells. n = 
three independent experiments. The uptake index represents the proportion of cells that show uptake of apoptotic material 
out of total cell present. The means were compared with respective controls using Dunnett's multiple mean comparison pro-
cedure (* p < 0.05). (D) Representative images showing different categories of cells found 30-min after BSA feeding. (E) Repre-
sentative images showing the two categories: No uptake; Uptake, where internalized apoptotic bodies/cells were present 
inside the macrophages.Orphanet Journal of Rare Diseases 2009, 4:29 http://www.ojrd.com/content/4/1/29
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Figure 4 (see legend on next page)Orphanet Journal of Rare Diseases 2009, 4:29 http://www.ojrd.com/content/4/1/29
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During the course of our experiments, we serendipitously
discovered that the BAL cells began to progressively
extend long processes, especially those cultured ex vivo for
longer than 7 days. In agreement with this phenomenon,
the cell size increased with increase in number of days
(Figure 4F). Because of the change in cell shape and size,
we asked whether there was an effect on the ability of
these cells to internalize BSA. Quantifying BSA uptake
revealed that the proportion of cells participating in the
uptake of BSA decreased over time, and was inversely
related to cell size (Figure 4F).
GM-CSF increases granulomatous structure formation
Remarkably, when these BAL cells were cultured ex vivo for
an even longer period of time (> 20 days), these cells
began to form previously uncharacterized granulomatous
structures (Figure 5). The formation of these structures
was reproducible under different conditions. The granulo-
mas formed ex vivo consisted of smaller spherical cells and
elongated cells. These clearly defined cells were primarily
found at the periphery of the granulomas (Figure 5A).
Although the precise nature of these structures is
unknown, given our observation that GM-CSF makes cells
more spherical, we asked whether incubation of these
cells with GM-CSF would reverse, or slow down the for-
mation of elongated cells and attenuate or prevent granu-
loma formation. Surprisingly, presence of GM-CSF (10
ng/ml) dramatically increased the number of granuloma-
tous structures present in the culture (Figure 5B). On the
other hand, the control BAL cells only became slightly
elongated. We performed a regression analysis on the
quantification of granulomas formed in each culture and
compared each condition using an F test (Figure 5B). The
analysis revealed that conditions were significantly differ-
ent from one another. Notably, culturing the cells in the
presence of both SP-D (1 μg/ml) and GM-CSF (10 ng/ml)
significantly reduced the formation of granulomas, com-
pared to GM-CSF alone (p < 0.05; Figure 5B). Together,
these results suggested that LPI BAL cells form granuloma-
tous structures spontaneously, and GM-CSF enhances
their formation. The data also suggest that SP-D can
reduce GM-CSF mediated increase in granuloma forma-
tion (p < 0.05).
Discussion
PAP in LPI is often untreatable and results in death. In this
study, we carefully characterized BALF and tissue samples
obtained from an LPI patient. The data revealed elevated
levels of protein and dying cells in the airways. In addi-
tion, large cholesterol crystals and abnormal tubular mye-
lin structures were found. Our primary cell culture assays
using Alexa-647 conjugated BSA and apoptotic Jurkat T
cells showed that pre-incubation of the LPI BAL cells with
SP-D and GM-CSF increased their innate immune func-
tions. Surprisingly, many of these LPI cells, but not the
control cells, became elongated and stopped internalizing
foreign material; eventually they formed granulomas ex
vivo. Notably, treating these cells with GM-CSF ex vivo dra-
matically increased granuloma formation. However, treat-
ing the cells with SP-D reduced GM-CSF-mediated
granuloma formation. Therefore, these findings may pro-
vide important clues for devising better treatment of PAP
in LPI patients.
Although various SLC7A7 mutations can cause LPI, the
importance of different mutations in the disease pheno-
type is not clearly established [45]. LPI is relatively fre-
quent in Finland and Italy [46,47], and in Japan, 1:119
individuals are heterozygous carriers for this LPI gene
mutations with estimated frequency of 1:50000 individu-
als living with LPI [48]. LPI has also been reported in
other countries where variable penetrance of specific
founder mutations was shown to be responsible for the
disease [37,49]; hence, many LPI individuals with
SLC7A7 mutations may be misdiagnosed.
This is the first report that shows LPI in a patient with
Dutch ancestry. Consistent with the definition of PAP
SP-D and GM-CSF affect the shape and size of the cells Figure 4 (see previous page)
SP-D and GM-CSF affect the shape and size of the cells. (A-D) Adherent viable cells were grown in the absence or 
presence of SP-D (1 μg/ml) and/or GM-CSF (10 ng/ml) for 24 h. (A) Cells without any added proteins have relatively the same 
size and shape. (B) In the presence of SP-D, more cells became elongated in shape (arrows). (C) In the presence of GM-CSF, 
more cells became small, round or oval (arrowheads). (D) In the presence of both SP-D and GM-CSF, both populations 
(arrowheads, oval; arrow, elongated) are present. (E) Average cell size shown in the above conditions. Presence of GM-CSF 
significantly reduced cell size, reflecting the formation of small and spherical/oval cells. The sizes of at least 50 cells were meas-
ured in each category. Data are presented as means ± SEM; n = two independent experiments. The means were compared 
with respective controls using Dunnett's multiple mean comparison procedure (* p < 0.05). (F) Over one week time, many 
BAL cells changed into elongated and stopped internalizing foreign materials (labeled BSA). Number of cells that actively inter-
nalize the foreign material was quantified from the randomly selected images obtained in uptake assays. The increase in cell size 
was associated with decrease in % cells that internalize BSA. For percent cells that actively internalize, data are presented as 
the proportion of cells that were able to take up Alexa fluor 647-conjugated BSA in total number of cells present. The mean 
values were compared with Day1 value using Dunnett's multiple mean comparison procedure (* p < 0.05).Orphanet Journal of Rare Diseases 2009, 4:29 http://www.ojrd.com/content/4/1/29
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LPI cells, but not the control cells, isolated from BALF spontaneously form granuloma Figure 5
LPI cells, but not the control cells, isolated from BALF spontaneously form granuloma. (A) While cells from the 
control BALF did not elongate to a greater degree, many LPI cells became highly elongated. LPI cells then formed granulomas 
while the control cells remained relatively unchanged (26 days ex vivo). All of these cells moved to one location and eventually 
formed granulomas over time. The formation of these granulomas was reproducible under different culturing conditions. 
Images represent randomly selected cells captured every 3-4 days. Bar, 100 μm. (B) Effect of SP-D and GM-CSF on granuloma 
formation. Treatment of cells with GM-CSF greatly enhanced the formation of granulomatous structures whereas SP-D 
reduced the effect of GM-CSF-mediated granuloma formation. Non-linear regression analysis and comparison by F-test 
revealed statistical differences in granuloma formation over the entire experimental period among these four different treat-
ments (p < 0.05).Orphanet Journal of Rare Diseases 2009, 4:29 http://www.ojrd.com/content/4/1/29
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[1,12,27], this patient's BALF had PAS positive material
(data not shown) and >100-fold protein levels compared
to control, as well as increased numbers of dead cells (Fig-
ure 1). High amount of cholesterol and several cholesterol
crystals were also seen (Figure. 2). These pathological
indices are consistent with reduced lung function seen in
these patients.
Although Western blot analyses showed that SP-D was
present in the BALF, some SP-D was modified or tightly
bound to other components. Furthermore, a considerable
amount of SP-D was partially cleaved (Figure 1D). These
conditions would render SP-D less functional [50,51].
Furthermore, electron microscopy analysis of the sur-
factant lipid pellets showed alterations in tubular myelin
structures; notably, the tubular myelin had circular lattice
structures, as opposed to the SP-A-mediated square lattice-
like structures that are typically seen in healthy humans
(Figure 1E and 1F) [43,52]. Tubular myelin with circular
lattice structures is not reported in normal human lungs,
but could be generated with SP-D and phosphatidylinosi-
tol, in vitro [43]. Since these lipid structures could trap SP-
D, together with the fact that there was degraded SP-D, we
suggest that the bioavailability of free SP-D is limited in
the airways of PAP lungs.
Electron microscopy analysis further revealed the pres-
ence of large numbers of cholesterol crystals in the sur-
factant consistent with previous reports on LPI with PAP
[32,33,39]. Since the cholesterol level is elevated in air-
ways and serum of idiopathic PAP patients [53], choles-
terol may be one of the important contributors of the
pathology in all types of PAP. High cholesterol levels in
the lung surfactant increases surface tension [54,55], and
thus may reduce overall lung function. Interestingly, lov-
astatin, a cholesterol-reducing drug, has been shown to
increase apoptotic cell clearance [56]. Therefore, we sug-
gest that it would be worthwhile to explore the possibility
of lowering cholesterol in the lungs while increasing dead
cell clearance. This may be an alternative treatment option
for reducing pulmonary complications in LPI patients.
Since GM-CSF [2,3,22,23,57-62] and SP-D deficiency [24-
26,42] cause a PAP-like phenotype, we examined their
potential therapeutic role ex vivo. Although both GM-CSF
and SP-D are usually present in the lungs, it is important
to determine whether the BAL cells isolated from the
patient respond to these proteins. We were able to show a
positive effect of GM-CSF and SP-D in the uptake of pro-
tein and apoptotic cells (Figure 3). These results are con-
sistent with the roles of GM-CSF and SP-D suggested by in
vivo mouse experiments [30,63,64]. Therefore, our results
show that, similar to wild type cells, "healthy" LPI cells
can respond to SP-D and GM-CSF effectively.
These healthy viable LPI cells however also formed granu-
lomatous structure ex vivo (Figure. 5). Within about one
week, many of these cells become elongated and large.
They stopped internalizing foreign materials regardless of
the presence or absence of SP-D or GM-CSF (Figure 5).
Some of the cells formed elongated fibers and connected
with each other whereas others migrated to a common
location and formed granulomatous structures. It is logi-
cal to consider that defective surfactant homeostasis [1-
7,22-26,42,57-62,65-68], accumulation of dead/dying
cells [30] and foamy macrophages [21,25,26,69], and
increased granulomas [39] would reduce lung function in
the patients with PAP and LPI. Therefore, alternative strat-
egies are necessary to treat PAP in these patients.
Aerosol [70,71] and subcutaneous [14,72] GM-CSF ther-
apy have been successful in treating some patients with
PAP [14,70-72]. Overexpression of GM-CSF in mouse
[20,73] and rat [74,75] lungs has been shown to increase
the recruitment of monocytes [20,75] and proliferation
[73] and differentiation of alveolar macrophages [20].
Under certain conditions, GM-CSF also increases granu-
loma formation [75] and fibrosis [74] in the lung. Subcu-
taneous GM-CSF therapy (6 μg/kg per day) has been tried
for treating PAP in another child with LPI, but was unsuc-
cessful because the administration of GM-CSF had side
effects and lead to excessive leukocytosis [34]. A recent
report described a successful therapeutic WLL on a 10-
year-old Italian boy with LPI who presented with PAP
[46]. The pulmonary condition in the patient described in
our report, however, did not improve after WLL, and the
patient eventually died of pulmonary insufficiency.
Conclusions
Our experiments using the primary cells isolated from the
LPI patient did not confirm the effectiveness of GM-CSF
alone in protein or apoptotic cell uptake assays; however,
when GM-CSF was added together with SP-D, the innate
immune potential of these LPI cells were enhanced. GM-
CSF also showed a remarkable increase in granulomatous
structure formation, but SP-D was able to reduce the neg-
ative effect of this cytokine. Taken together, our results
suggest that although GM-CSF is a possible therapeutic
molecule for treating patients with autoimmune idio-
pathic PAP, it may not be suitable for treating PAP in LPI
patients. We suggest that alternative approaches (e.g., stat-
ins) need to be considered for clearing dying cells and
cholesterol from the airways of these patients.
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